Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_assertion type Assertion NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_head.
- NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_assertion description "[The combination of IFN-gamma and CaM antagonists, including tamoxifen, may be a potential therapeutic modality for cholangiocarcinoma and possibly other malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_provenance.
- NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_assertion evidence source_evidence_literature NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_provenance.
- NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_assertion SIO_000772 14578204 NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_provenance.
- NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_assertion wasDerivedFrom befree-2016 NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_provenance.
- NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_assertion wasGeneratedBy ECO_0000203 NP418260.RALnyKdVu-X2Lhr6ALlvJVCUbGE3SaloRO1GFJTq9X-mE130_provenance.